



TZF Polfa is one of the most established pharmaceutical enterprises in the world, with over 200 years of tradition. Since 1823, the company has been committed to safeguarding patients' health and quality of life, adapting to their evolving needs, including those arising from lifestyle diseases.

Securing patient access to medicines is a priority for us, which is why we focus on manufacturing and supplying medicines classified as critical by the European Medicines Agency/ European Union. We support the healthcare system by improving access to therapies for everyone who needs them.

Our operations focus on four main drug categories: antibiotics, human insulins, dermatological medicines, and CNS drugs – supporting the central nervous system.

Across 11 production departments, nearly 25 million packages of finished products are manufactured per year, in 130 different forms and dosages. We offer a comprehensive portfolio of pharmaceutical dosage forms, specializing in tablets, capsules, powders for suspension, lyophilizates for preparing injectable solutions, injectable solutions and suspensions, gels, and pharmaceutical aerosols.

We are consistently expanding our production capabilities and the availability of medicines. Our in-house organic synthesis of active pharmaceutical ingredients (APIs) enables the horizontal integration of our manufacturing processes.

Over 200 years of experience and a team of more than 1,000 specialists guarantee the highest efficacy of the medicines we produce and their wide distribution to Polish pharmacies, hospitals, and more than 60 export markets, including Scandinavia, Central and Eastern Europe, Africa, Asia, and South America.

## Tarchomińskie Zakłady Farmaceutyczne "Polfa" S.A.

Sąd Rejonowy dla m.st. Warszawy w Warszawie XIV Wydział Gospodarczy Krajowego Rejestru Sądowego Kapitał zakładowy 184.913.610 zł (wpłacony w całości)


info@tzf.pl

+48 (22) 510 80 01















We are a trusted partner in the pharmaceutical industry, offering a comprehensive range of services in drug development, laboratory analysis, quality control, and contract manufacturing.

We operate based on diverse business models, such as **CDMO** (Contract Development and Manufacturing Organization), **CMO** (Contract Manufacturing Organization), **LICENCE-OUT**, **LICENCE-IN** and **co-DEV** (co-Development), tailoring our approach to each client's individual needs.

The need for continuous development and organizational improvement drives TZF Polfa to actively pursue innovative therapeutic solutions that meet the healthcare challenges of modern times. These factors inspired the establishment of the Center for the Development and Manufacturing of High-Potency Drugs – the only facility of its kind in Poland and across Central and Eastern Europe. The Center will specialize in manufacturing high-potency drugs, including those used in cancer treatment. This fulfills TZF Polfa's core mission: a commitment to patient safety and advancing healthcare. Always guided by the same message – a love for life. Polfa: dedicated to people, committed to care. Together, we can make the world a better place.



## Tarchomińskie Zakłady Farmaceutyczne "Polfa" S.A.

Sąd Rejonowy dla m.st. Warszawy w Warszawie XIV Wydział Gospodarczy Krajowego Rejestru Sądowego Kapitał zakładowy 184.913.610 zł (wpłacony w całości)



+48 (22) 510 80 01





